1. Home
  2. XGN

as 06-18-2024 9:30am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medical Specialities

Nasdaq

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Founded: N/A Country:
United States
United States
Employees: N/A City: VISTA
Market Cap: 33.9M IPO Year: 2019
Target Price: $7.00 AVG Volume (30 days): 45.4K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.09 EPS Growth: N/A
52 Week Low/High: $1.30 - $3.27 Next Earning Date: 08-05-2024
Revenue: $55,733,000 Revenue Growth: 20.12%
Revenue Growth (this year): 7.16% Revenue Growth (next year): 16.16%

XGN Daily Stock ML Predictions

Stock Insider Trading Activity of Exagen Inc. (XGN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
ABALLI JOHN XGN President and CEO May 16 '24 Buy $1.92 40,401 $77,569.92 40,401 SEC Form 4
Adawi Kamal XGN CFO and Corporate Secretary Feb 6 '24 Sell $1.95 6,738 $13,133.04 181,533 SEC Form 4

Share on Social Networks: